CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

autologous cd19/cd22 chimeric antigen receptor t-cells

Cell therapyexperimental

Clinical trial activity

53 trials · 54 clinical orgs · 0 marketing orgs

Phase 1
43
Phase 2
26
Phase 3
0
Phase 4
0

Earliest trial started May 5, 2017 (NCT03287804)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06815029Phase 1Jan 2, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06784726Phase 2Apr 1, 2025Regeneron, University of Washington
NCT07094477Phase 2Apr 1, 2025People's Liberation Army of China
NCT06854159Phase 2Apr 1, 2025National Cancer Institute (NCI), University of California, Davis
NCT06880913Phase 1/Phase 2 (Phase 2)Nov 14, 2024Hebei Senlang Biotechnology Inc., Ltd., Peking University
NCT06911710Phase 1/Phase 2 (Phase 2)Nov 9, 2024Government of China, Tianjin Medical University
NCT06735495Phase 1/Phase 2 (Phase 2)Nov 4, 2024Government of China, Huazhong University of Science and Technology
NCT06559189Phase 1Sep 27, 2024University of Colorado, Denver
NCT06213636Phase 1/Phase 2 (Phase 2)Jul 10, 2024Essen Biotech
NCT05993611Phase 1Jan 17, 2024City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06014762Phase 1Dec 1, 2023Poseida Therapeutics, Inc., Roche
NCT06104592Phase 2Oct 20, 2023Gilead Sciences, University of South Florida
NCT06078306Phase 2Oct 10, 2023Soochow University
NCT05800405Early Phase 1 (Phase 1)Jul 20, 2023City of Hope National Medical Center, National Cancer Institute (NCI)
NCT05442515Phase 1/Phase 2 (Phase 2)Dec 29, 2022National Cancer Institute (NCI)
NCT05098613Phase 1Oct 31, 2022University of Colorado, Denver
NCT05797948N/AJul 1, 2022Soochow University
NCT05388695Phase 1Apr 8, 2022Hebei Senlang Biotechnology Inc., Ltd., Huazhong University of Science and Technology
NCT05202782Phase 2Mar 21, 2022National Cancer Institute (NCI), Northwestern University
NCT06081478Phase 2Jan 18, 2022Capital Medical University
Showing 20 of 53 trials
Page 1 / 3

Organizations

Research & Development (54)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government11222018
Jiao Tong UniversityAcademic/Hospital5522017
Soochow UniversityAcademic/Hospital5422017
City of Hope National Medical CenterAcademic/Hospital4412018
Hebei Senlang Biotechnology Inc., Ltd.For profit4332021
Immune TherapeuticsFor profit3012021
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdFor profit3112017
ShanXi Cancer HospitalAcademic/Hospital3012021
Shanxi Medical UniversityAcademic/Hospital3312021
University of WashingtonAcademic/Hospital3322017
Autolus LimitedFor profit2212017
Chinese Academy of Medical SciencesAcademic/Hospital2112019
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyGovernment2212018
GenScriptFor profit2012017
Government of ChinaGovernment2012024
Huazhong University of Science and TechnologyAcademic/Hospital2122022
People's Liberation Army of ChinaGovernment2222017
Sponsor GmbHAcademic/Hospital2012017
Stanford UniversityAcademic/Hospital2212017
University of California, DavisAcademic/Hospital2222021
54 organizations
Page 1 / 3